Remibrutinib (Rhapsido)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.756 alerts
Get alerted when Policy CP.PHAR.756 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Rhapsido in adult members with chronic spontaneous urticaria or symptomatic dermographism. It applies to providers seeking coverage under Ambetter Nevada commercial, marketplace/ICHRA, or Medicaid benefits.
The required antihistamine trial dose was revised from the maximum indicated dose to the maximum tolerated dose, allowing up to four-fold standard dosing consistent with practice guidelines.
The revision history records addition of a newly approved symptomatic indication.
The revision history records addition of the ICHRA line of business.
References were reviewed and updated during the 4Q 2026 annual review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.